This site is intended for US healthcare professionals only

Previously treated epNET efficacy data

On This Page:

#1 prescribed oral therapy in 2L + NET

Among FDA-approved oral therapies in advanced NET. Based on IQVIA BrandImpact data as of 1/26. Subject to change without notice.

CABOMETYX doubled median PFS in epNET1

60% reduction in risk of progression or death  

PFS results in epNET patients across select disease characteristics2

Subgroups were not powered to show differences between treatment arms, and results should be considered hypothesis generating.

Exploratory analysis

PFS results in patients with lung/thymus site of origin3

Observed outcomes should be interpreted with caution because of the relatively small subgroup size. Subgroups were not powered to show differences between treatment arms, and results should be considered hypothesis generating.

Exploratory analysis

PFS results in Grade 3 patients across pNET and epNET4

Observed outcomes should be interpreted with caution because of the relatively small subgroup size. Subgroups were not powered to show differences between treatment arms, and results should be considered hypothesis generating.

The Grade 3 analysis pooled 24 patients enrolled in the epNET and pNET cohorts of the CABINET trial.

pNET (n=l2): PFS (median): 13.5 months (95% Cl: 7.6-NE) vs 1.5 months with placebo (95% Cl: 0.9-NE); HR=0.00 (95% Cl: 0.00-NE).

epNET (n=l 2): PFS (median): 6.5 months (95% Cl: 3.0-NE) vs 4.2 (3.0 -NE) with placebo (95% Cl: 0.3-NE); HR=0.45 (95% Cl: 0 .09-2.32).

NE=not estimable.

Descriptive analysis

Tumor response with CABOMETYX in epNET1,5

epNET

CABOMETYX achieved 69% disease control

*

All responses confirmed were partial responses.2

†

Disease control rate is defined as the percentage of patients with a complete response, partial response, or stable disease, as measured by RECIST v1.1.5

‡

Stable disease is defined as neither sufficient shrinkage to qualify as partial response nor sufficient increase to qualify as PD.6 Stable disease may reflect the natural history of disease rather than any effect of the drug.

Descriptive analysis

Reduction in target lesions from baseline2,7

Of the 203 epNET ITT patients, 174 were evaluable (n=111 in the CABOMETYX arm, n=63 in the placebo arm).

Interpret data with caution.

No formal statistical testing was conducted for the tumor assessment waterfall plots.

Best reduction is maximum reduction in sum of diameters of target lesions. Patients with target lesion at baseline and at least 1 on-treatment tumor assessment are included. Some patients are not represented due to lack of evaluable postbaseline assessment, censoring before first evaluable postbaseline assessment, lack of target lesions, and/or incomplete or inevaluable target-lesion assessment. Data from time points after the first date of any of the censoring events defined for the primary PFS analysis were excluded.5

§

Each vertical line represents 1 patient.7

II

Indicates confirmed partial responses per BIRC.7

Updated analysis

OS results from CABINET1

OS data were not mature at the time of the updated analysis and may be impacted by crossover

epNET

Updated OS

63%

Deaths
CABOMETYX (n=132)

60%

Deaths
Placebo (n=67)

(HR=1.05; 95% CI: 0.71-1.54)

37% of placebo patients crossed over to open-label CABOMETYX

63%

Deaths
CABOMETYX (n=132)

60%

Deaths
Placebo (n=67)

(HR=1.05; 95% CI: 0.71-1.54)

37% of placebo patients crossed over to open-label CABOMETYX

The CABINET trial was unblinded early and patients were allowed to cross over to open-label CABOMETYX regardless of whether they had experienced progression. A later updated OS analysis was conducted when 123 deaths were observed in the epNET cohort.

National Comprehensive Cancer Network® (NCCN®)

Cabozantinib (CABOMETYX) is a recommended systemic anti-tumor therapy for certain patients with:

  • Pancreatic NET (Grade 1/2)**
  • Gastrointestinal tract NET (Grade 1/2)**
  • Lung/thymus NET
  • Grade 3 NET**

**Well-differentiated.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

See pNET Efficacy Data
See Safety Data
Back to Top

2L=second line; BIRC=blinded independent review committee; CI=confidence interval; DCR=disease control rate; ECOG PS=Eastern Cooperative Oncology Group performance status; epNET=extrapancreatic neuroendocrine tumors; FDA=Food and Drug Administration; HR=hazard ratio; ITT=intent to treat; Lu-177=lutetium-177; NE=not estimable; NET=neuroendocrine tumor(s); ORR=overall response rate; OS=overall survival; PD=progressive disease; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors; RECIST=Response Evaluation Criteria in Solid Tumors; SSA=somatostatin analogue.

References:

  1. CABOMETYX® (cabozantinib) Prescribing Information. Exelixis, Inc.
  2. Chan JA, Geyer S, Zemla T, et al. Phase 3 trial of cabozantinib in previously treated advanced neuroendocrine tumors. N Engl J Med. 2024; Published online September 16, 2024. doi:10.1056/NEJMoa2403991.
  3. Wolin EM, Zemla T, Geyer S, et al. Efficacy and safety of cabozantinib for advanced lung and thymic neuroendocrine tumors after progression on prior therapy: subgroup analysis of Phase 3 CABINET trial (Alliance A021602). Poster presented at: European Society for Medical Oncology Congress: October 17-21, 2025.
  4. Strosberg JR, Zemla T, Geyer S, et al. Efficacy and safety of cabozantinib for advanced Grade 3 NETs after progression on prior therapy: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Poster presented at: European Neuroendocrine Tumor Society Conference for the Diagnosis and Treatment of Neuroendocrine Tumour Disease; March 5-7, 2025.
  5. Data on file. Exelixis, Inc.
  6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
  7. Chan JA, Geyer S, Zemla T, et al. Phase 3 trial of cabozantinib in previously treated advanced neuroendocrine tumors [supplementary appendix]. N Engl J Med. 2024; Published online September 16, 2024. doi:10.1056/NEJMoa2403991.
  8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines·) for Neuroendocrine and Adrenal Tumors V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 1, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no representations or warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: CABOMETYX can cause severe and fatal hemorrhages. The incidence of Grade 3-5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3-4 hemorrhage and before surgery. Do not administer to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

Perforations and Fistulas: Fistulas, including fatal cases, and gastrointestinal (GI) perforations, including fatal cases, each occurred in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or GI perforation.

Thromboembolic Events: CABOMETYX can cause arterial or venous thromboembolic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events have occurred. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events.

Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. In CABINET (n=195), hypertension occurred in 65% (26% Grade 3) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with antihypertensive therapy or for hypertensive crisis.

Cardiac Failure: CABOMETYX can cause severe and fatal cardiac failure. Cardiac failure occurred in 0.5% of patients treated with CABOMETYX as a single agent, including fatal cardiac failure in 0.1% of patients. Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Withhold and resume at a reduced dose upon recovery or permanently discontinue depending on the severity.

Diarrhea: CABOMETYX can cause diarrhea and it occurred in 62% (10% Grade 3) of treated patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1; resume at a reduced dose.

Palmar-Plantar Erythrodysesthesia (PPE): CABOMETYX can cause PPE and it occurred in 45% of treated patients (13% Grade 3). Withhold CABOMETYX until PPE resolves or decreases to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.

Hepatotoxicity: CABOMETYX in combination with nivolumab in RCC can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. Monitor liver enzymes before initiation of treatment and periodically. Consider more frequent monitoring as compared to when the drugs are administered as single agents. Consider withholding CABOMETYX and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity.

Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity.

Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome.

Osteonecrosis of the Jaw (ONJ): CABOMETYX can cause ONJ and it occurred in <1% of treated patients. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution; resume at a reduced dose.

Impaired Wound Healing: CABOMETYX can cause impaired wound healing. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): CABOMETYX can cause RPLS. Perform evaluation for RPLS and diagnose by characteristic finding on MRI any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Thyroid Dysfunction: CABOMETYX can cause thyroid dysfunction, primarily hypothyroidism, and it occurred in 19% of treated patients (0.4% Grade 3). Assess for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitor for signs and symptoms during treatment.

Hypocalcemia: CABOMETYX can cause hypocalcemia, with the highest incidence in DTC patients. Based on the safety population, hypocalcemia occurred in 13% of CABOMETYX patients (2% Grade 3 and 1% Grade 4).

Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume CABOMETYX at a reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity.

Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose.

ADVERSE REACTIONS

The most common (≥20%) adverse reactions are:

CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation.

CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.

Strong or Moderate CYP3A4 Inducers: If coadministration with strong or moderate CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John’s wort.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.

Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment.

Pediatric Use: Physeal widening has been observed in children with open growth plates when treated with CABOMETYX. Physeal and longitudinal growth monitoring is recommended in children (12 years and older) with open growth plates. Consider interrupting or discontinuing CABOMETYX if abnormalities occur. The safety and effectiveness of CABOMETYX in pediatric patients less than 12 years of age have not been established.

Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Indications

CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). 

CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 

CABOMETYX® (cabozantinib) is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET). 

CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extrapancreatic neuroendocrine tumors (epNET)​. 

CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. 

CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.

CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). 

CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 

CABOMETYX® (cabozantinib) is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET). 

CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extrapancreatic neuroendocrine tumors (epNET). 

CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. 

CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.

OPDIVO® and the related logo are registered trademarks of Bristol-Myers Squibb Company.

visual type treatment for Exelixis logo

© 2025 Exelixis, Inc.  03/26 CA-3880

Consumer Health Data Notice Your Privacy Choices